Cargando…

Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1

BACKGROUND: The cyclin-dependent kinase 7 (CDK7) inhibitor THZ1 represses multiple cancer cells. However, its tumor-repressive efficiency in wild-type p53 breast cancer cells remains controversial. METHODS: We conducted various assays, including CCK8, colony formation, flow cytometry, western blotti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yueyuan, Zhang, Zhihao, Mi, Xuguang, Li, Mingxi, Huang, Dan, Song, Tingting, Qi, Xiaoyan, Yang, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442925/ https://www.ncbi.nlm.nih.gov/pubmed/36058938 http://dx.doi.org/10.1186/s12964-022-00837-z

Ejemplares similares

p53–GSDME Elevation: A Path for CDK7 Inhibition to Suppress Breast Cancer Cell Survival
por: Wang, Yueyuan, et al.
Publicado: (2021)

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition
por: Peng, Jingyu, et al.
Publicado: (2021)

Cdk6: At the interface of Rb and p53
por: Nebenfuehr, Sofie, et al.
Publicado: (2018)

Temperature sensitivity for conformation is an intrinsic property of wild-type p53.
por: Hainaut, P., et al.
Publicado: (1995)

Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation
por: Ma, Xinqi, et al.
Publicado: (2018)

Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors
por: Schwermer, Melanie, et al.
Publicado: (2015)

Comparable radiation sensitivity in p53 wild-type and p53 deficient tumor cells associated with different cell death modalities
por: Li, Ping, et al.
Publicado: (2021)

The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type p53 but Not Mutant p53 to Topotecan Treatment
por: Li, Dan-Dan, et al.
Publicado: (2012)

P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9
por: Tian, Xiaobing, et al.
Publicado: (2021)

Elimination of wild-type P53 mRNA in glioblastomas showing heterozygous mutations of P53
por: Szybka, M, et al.
Publicado: (2008)

Interaction of p53 with the CCT Complex Promotes Protein Folding and Wild-Type p53 Activity
por: Trinidad, Antonio Garcia, et al.
Publicado: (2013)

p53 β-hydroxybutyrylation attenuates p53 activity
por: Liu, Kun, et al.
Publicado: (2019)

Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development
por: Kazantseva, Marina, et al.
Publicado: (2018)

BRD7 Stabilizes P53 via Dephosphorylation of MDM2 to Inhibit Tumor Growth in Breast Cancer Harboring Wild-type P53
por: Luo, Yanwei, et al.
Publicado: (2022)

Functional Diversity of p53 in Human and Wild Animals
por: Li, Yi, et al.
Publicado: (2019)

Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo.
por: Ponchel, F., et al.
Publicado: (1998)

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients
por: Bourdon, Jean-Christophe, et al.
Publicado: (2011)

Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
por: Lu, Phong, et al.
Publicado: (2019)

CDK4 inhibition diminishes p53 activation by MDM2 antagonists
por: Sriraman, Anusha, et al.
Publicado: (2018)

The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma
por: Borowczak, Jędrzej, et al.
Publicado: (2022)

THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
por: Cayrol, Florencia, et al.
Publicado: (2017)

The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells
por: Garufi, Alessia, et al.
Publicado: (2015)

p53 Amino-Terminus Region (1–125) Stabilizes and Restores Heat Denatured p53 Wild Phenotype
por: Sharma, Anuj Kumar, et al.
Publicado: (2009)

The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells
por: Mortensen, Anja Charlotte Lundgren, et al.
Publicado: (2019)

Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1
por: Bollu, Lakshmi Reddy, et al.
Publicado: (2020)

Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents
por: Michaelis, M, et al.
Publicado: (2012)

EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma
por: Ding, Jie, et al.
Publicado: (2022)

p53 isoforms change p53 paradigm
por: Bourdon, JC
Publicado: (2014)

Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway
por: Xie, Haibiao, et al.
Publicado: (2021)

Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms
por: Butturini, Elena, et al.
Publicado: (2021)

Upregulation of p16(INK4A) and Bax in p53 wild/p53-overexpressing crypts in ulcerative colitis-associated tumours
por: Yoshida, T, et al.
Publicado: (2004)

FUCA1 is induced by wild-type p53 and expressed at different levels in thyroid cancers depending on p53 status
Publicado: (2017)

Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
por: Cayrol, Florencia, et al.
Publicado: (2017)

SIRT7 Deacetylates STRAP to Regulate p53 Activity and Stability
por: Yu, Miao, et al.
Publicado: (2020)

Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors
por: Dong, Peixin, et al.
Publicado: (2015)

ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942
por: Sava, Georgina P., et al.
Publicado: (2019)

Cdk2 Is Required for p53-Independent G(2)/M Checkpoint Control
por: Chung, Jon H., et al.
Publicado: (2010)

Activation of CDK4 by Tax chemosensitizes p53-mutant cells to DNA damage
por: Semmes, O John, et al.
Publicado: (2014)

ING5 Is Phosphorylated by CDK2 and Controls Cell Proliferation Independently of p53
por: Linzen, Ulrike, et al.
Publicado: (2015)

Understanding p53 functions through p53 antibodies
por: Sabapathy, Kanaga, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sbj8o1jprrvi3llp781nqlsul7